Back to the Future: Clinical Experience with and Access to Lipid-Lowering Agents of the Past, Present, and Future
WebcastFaculty
OVERVIEW
Back to the Future: Clinical Experience with and Access to Lipid-Lowering Agents of the Past, Present, and Future is organized by Vindico Medical Education and will be held during Aug 11, 2017 - Aug 11, 2018.
The target audience for this medical event is physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management. This CME Conference has been approved for a maximum of 2.0 AMA PRA Category 1 Credits.
Conference Objectives are :
At the conclusion of this activity, all participants should be able to:
• Translate the historical indications and prescribing guidelines of statins;
• Discuss how early outcomes trials and usage guidelines of novel therapies influenced current clinical practices in CVD prevention;
• Summarize the potential for PCSK9 inhibitor indication expansion;
• Analyze the use of omega-3 fatty acids in patient populations wherein outcomes studies have not been conducted;
• Identify emerging lipid drug targets that may be important in ASCVD risk reduction;
• Utilize specialized treatment strategies for the management of patients with multiple risk factors;
• Discuss strategies to improve the knowledge, skills or performance of the healthcare team.
Additional details will be posted as soon as they are available.
The target audience for this medical event is physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management. This CME Conference has been approved for a maximum of 2.0 AMA PRA Category 1 Credits.
Conference Objectives are :
At the conclusion of this activity, all participants should be able to:
• Translate the historical indications and prescribing guidelines of statins;
• Discuss how early outcomes trials and usage guidelines of novel therapies influenced current clinical practices in CVD prevention;
• Summarize the potential for PCSK9 inhibitor indication expansion;
• Analyze the use of omega-3 fatty acids in patient populations wherein outcomes studies have not been conducted;
• Identify emerging lipid drug targets that may be important in ASCVD risk reduction;
• Utilize specialized treatment strategies for the management of patients with multiple risk factors;
• Discuss strategies to improve the knowledge, skills or performance of the healthcare team.
Additional details will be posted as soon as they are available.
SPECIALITIES
Endocrinology, Metabolism and Diabetes
Quick Links